Barbier, A J <br/><br/>
The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.  [electronic resource] 

 -  Molecular genetics and metabolism  Nov 2013 
 - 303-10 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article 
<br/><br/><label>ISSN: </label>1096-7206 
<br/><br/><label>Standard No.: </label>10.1016/j.ymgme.2013.08.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intravenous<br/>Adolescent<br/>Adult<br/>Antibodies--immunology<br/>Child<br/>Child, Preschool<br/>Enzyme Replacement Therapy--adverse effects<br/>Genotype<br/>Glycoproteins--genetics<br/>Glycosaminoglycans--urine<br/>Humans<br/>Iduronate Sulfatase--administration & dosage<br/>Liver--metabolism<br/>Mucopolysaccharidosis II--drug therapy<br/>Organ Size<br/>Spleen--metabolism<br/>Treatment Outcome<br/>Young Adult